Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 17/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13760401 | 0.96 | MAOA (0.62) | MAOACYP3A4CYP2D6CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL1383835 | 0.85 | MAOA (0.52) | MAOA | |
| SCHEMBL1380483 | 0.85 | MAOA (0.77) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13089916 | 0.84 | CYP3A4 (0.51) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13099997 | 0.81 | MAOA (0.66) | MAOACYP3A4CYP2D6CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL1382546 | 0.81 | CALML3 (0.46) | MAOACYP3A4CYP2C9 | |
| SCHEMBL13089915 | 0.81 | MAOA (0.65) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13089907 | 0.80 | MAOA (0.56) | MAOA | |
| SCHEMBL10197417 | 0.77 | MAOA (0.81) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10261492 | 0.77 | MAOA (0.81) | MAOACYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4739229-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1699784-A4 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2008-09-03 | — | — | EP | claimed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | claimed |
| EP-1699784-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | Dong-A Pharmaceutical Co., Ltd. (KR) | 2006-09-13 | — | — | EP | claimed |
| WO-2005058886-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2005-06-30 | — | — | WO | claimed |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2020-03-12 | — | — | US | disclosed |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2018-12-06 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-02-23 | — | — | US | disclosed |
| US-9163043-B2 | Oxazolidinone derivatives | DONG-A ST CO., LTD. (KR) | 2015-10-20 | — | — | US | disclosed |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2014-11-27 | — | — | US | disclosed |
| EP-1699784-B1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2011-06-29 | — | — | EP | disclosed |
| EP-2305657-A2 | Oxazolidinone derivatives | Dong-A Pharmaceutical Co., Ltd. (KR) | 2011-04-06 | — | — | EP | disclosed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| EP-1699784-A4 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2008-09-03 | — | — | EP | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| EP-1699784-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | Dong-A Pharmaceutical Co., Ltd. (KR) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005058886-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885CYP3A4 46/4885CYP2D6 94/4885 |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885CYP3A4 46/4885CYP2D6 94/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | MAOA 4398/4885CYP3A4 68/4885CYP2D6 858/4885 |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885CYP3A4 46/4885CYP2D6 94/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | MAOA 3819/4885CYP3A4 93/4885CYP2D6 460/4885 |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885CYP3A4 46/4885CYP2D6 94/4885 |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885CYP3A4 46/4885CYP2D6 94/4885 |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885CYP3A4 46/4885CYP2D6 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.